academic article

• Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial..  The Lancet. Oncology.  17:1558-1568. 2016
• Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma. 2015